TREATMENT OF VIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME
The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential a...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
01.03.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2). |
---|---|
Bibliography: | Application Number: EP20210728669 |